Home · Products · Diabetes
Products · Diabetes
Screening, diagnosis and long-term control.
SHD supports the screening, diagnosis and monitoring of diabetes and metabolic disorders. Immunoassay markers such as insulin and C-peptide are available on the INNOVIQURE CLIA platform, complemented by point-of-care testing solutions — helping laboratories and clinics manage diabetes care with reliable, reproducible results.
3 products
HbA1cInsulinC-Peptide
Glycated haemoglobin (HbA1c) for the diagnosis and long-term monitoring of diabetes and glycaemic control.
Quantitative insulin assay on the INNOVIQURE CLIA platform — supports assessment of insulin secretion and resistance.
Quantitative C-peptide assay on the INNOVIQURE CLIA platform — evaluates endogenous insulin production and beta-cell function.
248CLIA assay menuThe automated immunoassay range
▤Technical documentsIFUs, certificates, declarations
✉Request informationPricing, samples, availability
Product availability and regulatory status may vary by country or region.
